Amgen Inc
Change company Symbol lookup
Select an option...
AMGN Amgen Inc
BAC Bank of America Corp
CLOV Clover Health Investments Corp
HRL Hormel Foods Corp
DD Dupont De Nemours Inc
PSRU Valiant Eagle Inc
CRM Salesforce.Com Inc
VLYPP Valley National Bancorp
FEMKX Fidelity® Emerging Markets Fund
XPEV Xpeng Inc

Health Care : Biotechnology | Large Cap Value
Company profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.


Last Trade
0.24 (0.11%)
B/A Size

Market Hours

Closing Price
Day's Change
-1.35 (-0.59%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:



All providers
Yesterday's News, March 01, 2021
During Kidney Month, American Kidney Fund Marks Its 50th Anniversary by Honoring Patient Milestones

ROCKVILLE, MD / ACCESSWIRE / March 1, 2021 / Fifty years ago, a small group of friends created a nonprofit that in its first year saved the lives of 79 people with kidney failure, and a mission was born. This Kidney Month, the American Kidney Fund...(Accesswire)

February 26, 2021
Tezepelumab Is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients

Positive full results from the pivotal NAVIGATOR Phase III trial showed AstraZeneca and Amgen's tezepelumab demonstrated a statistically significant and clinically meaningful(1) reduction in the annualized asthma exacerbation rate (AAER) in severe...(BusinessWire)

Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive full results from the pivotal NAVIGATOR Phase 3 trial, which showed the potential of tezepelumab to be a first-in-class medicine in severe asthma. When added to standard of care (SoC)...(PR Newswire)

February 25, 2021
American Kidney Fund Announces 2021 Class of Corporate Members Aligned in Fighting Kidney Disease

ROCKVILLE, MD / ACCESSWIRE / February 25, 2021 / The American Kidney Fund (AKF) today announced the 2021 class of Members in its Corporate Membership Program. Corporate Members form a strategic partnership with AKF, helping AKF to fight on all...(Accesswire)

February 24, 2021
Wearable Injectors Market Size to Reach USD 15.66 Billion by 2028 | Increasing Demand for More Innovative Devices and Solutions to Improve Quality Of Life Of Patients are Factors Driving Industry Growth, says Emergen Research

The global wearable injectors market size is projected to reach USD 15.66 Billion by 2028 at a CAGR of 11.2% over the forecast period, according to latest analysis by Emergen Research. This steady growth can be attributed to increasing challenges...(Globe Newswire)

Amgen To Present At The Cowen 41st Annual Healthcare Conference

Amgen (NASDAQ:AMGN) will present at the Cowen 41st Annual Virtual Healthcare Conference at 12:50 p.m. ET on Thursday, March 4, 2021. Murdo Gordon, executive vice president of Global Commercial Operations and Peter H. Griffith, executive vice...(PR Newswire)

February 23, 2021
Worldwide BiTE Antibodies Industry to 2025 - Players Include Amgen, Bayers & Micromet Among Others

The "Global BiTE Antibodies Market , Price, Sales & Clinical Trials Insight 2025" report has been added to's offering. This report reviews about the wide spread applications of the market and how it has been able to...(Globe Newswire)

February 22, 2021
Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting on Friday, Feb. 26, at 1:00 p.m. ET. David M. Reese, M.D., executive...(PR Newswire)

North America Osteoporosis Treatment Market to Reach USD 8.29 Billion with 6.6% CAGR by 2027; Increasing Prevalence of Osteoporosis to Stoke Demand: Fortune Business Insights(TM)

The North America osteoporosis treatment market size is expected to gain momentum by reaching USD 8.29 billion by 2027 while exhibiting a CAGR of 6.6% between 2020 and 2027. This is attributable to the increasing prevalence of osteoporosis and the...(Globe Newswire)

February 18, 2021
Universal PropTech Inc. Invests in and Secures defined Agency Rights for ISBRG Corp.'s SpotLight-19(C) Technology Designed to Detect Covid-19 Non-Invasively in Under One Minute

Toronto, Ontario--(Newsfile Corp. - February 18, 2021) - Universal PropTech Inc. (TSXV: UPI) ("UPI" or the "Company") is pleased to announce that it has completed an investment in ISBRG Corp. ("ISBRG") for a minority interest, and secured agency...(Newsfile)

February 16, 2021
FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for sotorasib for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)...(PR Newswire)

More Than 250 Companies Transform Regulatory with Veeva Vault RIM Applications

Veeva Systems (NYSE: VEEV) today announced that more than 250 organizations are using Veeva Vault RIM applications for end-to-end regulatory information management. A growing number of emerging biotechs and enterprise companies, including 12 of the...(BusinessWire)

More Than 250 Companies Transform Regulatory with Veeva Vault RIM Applications

Veeva Systems (NYSE: VEEV) today announced that more than 250 organizations are using Veeva Vault RIM applications for end-to-end regulatory information management. A growing number of emerging biotechs and enterprise companies, including 12 of the...(BusinessWire)

AmMax Bio to Participate in the 41st Annual Cowen Health Care Conference

AmMax Bio, Inc. ("AmMax"), a private clinical-stage biopharmaceutical company focused on developing first-in-class or best-in-class treatments with its proprietary dual anti-inflammatory/anti-fibrotic therapeutic platform targeting the...(BusinessWire)

February 15, 2021
$132.6 Billion Global Immuno-oncology Market to 2025 - Players Include Amgen, AstraZeneca and Novartis Among Others -

The "I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market" report has been added to's offering. This study explores the global immuno-oncology (I-O) market's evolution from 2020 to 2025. An extensive...(BusinessWire)

Europe Cell and Gene Therapy Market Report 2021-2026: Prominent Players are Novartis, Spark Therapeutics, Amgen, Gilead Sciences & Organogenesis

The "Europe Cell and Gene Therapy Market - Industry Outlook and Forecast 2021-2026" report has been added to's offering. In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Europe Cell and...(Globe Newswire)

February 12, 2021
Leukemia Therapeutics Market Size Worth USD 27.78 Billion at 8.1% CAGR; Industry Leaders Such as Pfizer and Bristol-Myers to Focus Investments on Advancing Clinical Trials: Fortune Business Insights(TM)

The global leukemia therapeutics market size is projected to reach USD 27.78 billion by 2027, exhibiting a CAGR of 8.1% during the forecast period. The increasing demand for enhanced treatments for blood cancers amid the COVID-19 pandemic will...(Globe Newswire)

February 11, 2021
U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent(R) (alirocumab) Patent Litigation

Upholds decision by U.S. District Court to invalidate Amgen's patent claims directed to PCSK9 antibodies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the United States Court of Appeals for the Federal Circuit upheld the...(PR Newswire)

February 10, 2021
Worldwide Industry for Erythropoietin to 2030 - Featuring Amgen, Roche and Pfizer Among Others -

The "Erythropoietin (EPO) Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to's offering. This report provides strategists, marketers and senior management with the critical information they need...(BusinessWire)

February 09, 2021
Amgen To Present At Guggenheim Healthcare Talks Oncology Day

Amgen (NASDAQ:AMGN) today announced that Greg Friberg, vice president and global oncology therapeutic area head at Amgen, will participate in a fireside chat as part of the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, Feb. 12 at 12:30...(PR Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.